Oxoprolinic short peptides – potential pharmacological means of hypolidemic and antitrombotic actions

   


1. Institute of Molecular Genetics RAS, Moscow, Russia
2. Lomonosov Moscow State University, Faculty of Biology, Moscow, Russia
Type: Experimental study
DOI: 10.18097/PBMC20176306546      PubMed Id: 29251617
Year: 2017 vol: 63  issue:6  pages: 546-552
Abstract: One of the most urgent and important tasks of modern biological and medical research is the search and research of pharmacological agents that combine lipid-lowering and antithrombotic effects in the organism. The unique effects of the regulatory peptides of the oxoproline series (5-oхo-Pro-His-Pro-NH2, 5-oxo-Pro-Trp-Pro and 5-oxo-Pro-Arg-Pro or 5-oхo-Pro-His-Pro-NH2, Pyr-Trp-Pro and Pyr-Arg-Pro) have been found in rats with hypercholesterolemia (metabolic syndrome). Multiple intranasal of these peptides to animals with developed hypercholesterolemia increased anticoagulant, fibrinolytic and antiplatelet potential of the blood and simultaneously lowered increased concentrations of total cholesterol, low-density lipoprotein cholesterol and triglycerides. In addition, they contributed to the normalization of blood glucose levels. A week after the last admistration of these peptides, the hypocholesterolemic, normoglycemic and anticoagulant effects persisted. The relationship between the structure of peptides of the oxoproline series and their functional properties is discussed. A conclusion is made about the prospects of further studies of oxoproline peptides as drugs that combine antithrombotic effects with the improvement of fat metabolism in the body.
Download PDF:
Reference: Myasoedov N.F., Lyapina L.A., Andreeva L.A., Obergan T.Yu., Grigoryeva M.E., Shubina T.A., Oxoprolinic short peptides – potential pharmacological means of hypolidemic and antitrombotic actions, Biomeditsinskaya khimiya, 2017, vol: 63(6), 546-552.
References
 2018(Vol:64)
 2017(Vol:63)
 2016(Vol:62)
 2015(Vol:61)
 2014(Vol:60)
 2013(Vol:59)
 2012(Vol:58)
 In press